Special Drug Use-results Surveillance of Tabrecta Tablets

Novartis

Status: Completed

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: Tabrecta tablets

Study type: Observational

Funder types: Industry

Identifiers

NCT04575025

CINC280AJP01

Details and patient eligibility

About

This study was an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study collected all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient was up to 1 year (52 weeks)

Enrollment: 109 patients

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period

Exclusion criteria

-

Trial design

109 participants in 1 patient group

Tabrecta tablets

Description:

Patients administered Tabrecta by prescription

Treatment:

Drug: Tabrecta tablets